TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of subsequent sequential postoperative intraperitoneal chemotherapy courses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with adequate antimicrobial therapy without carbapenem at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of gentle dilation
Endpoint domain: Adverse events/effects
Primary endpoint: Sialic acid levels in stage 1 periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sialic acid levels in stage 2 periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL10 levels in stage 1 periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL10 levels in stage 2 periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Good Birth Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fatigue severity and interference in daily activities
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Sleep quality via objectively measured sleep efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Grade 3 or above severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Peripheral Eosinophil Count at Day 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in patient estimated gluten intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Celiac disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IgA antibody to tissue transglutaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Hours of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Days With 4 or More Hours of Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching relapse criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Dead or With VT Recurrence at One Year
Endpoint domain: Mortality/survival
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of MLDL1278A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic rhinitis medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of periodontal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change in tumor volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surgeon's confirmation of the ability to place a dental implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in Under Eye Swelling and Dark Circles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) (0-infinity) eptinezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants receiving the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: speed of symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Patient-Reported Eye Dryness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TB screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Curve for Rewarming of Each Finger After Cold Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coenzyme Q10 Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IW001
Endpoint domain: Adverse events/effects
Primary endpoint: Survival to end stage lung disease
Endpoint domain: Mortality/survival
Primary endpoint: Lung function parameter: FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung function parameters: FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung function parameters: FEF75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative body mass composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CTCAE Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: number of mature oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Live birth rate per embryo thawed
Endpoint domain: Mortality/survival
Primary endpoint: Mean change of the average hand sweating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with >2 grade improvement in HDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative protein balance (leucine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: effective regurgitant orifice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proximal isovelocity surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in bioavailability of ethanol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in number of blisters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative incision infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Modified mini mental state examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Femoral and tibial tunnel location accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: extent of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduced amygdala reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hepatic encephalopathy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary Arterial Systolic Pressure at Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Atrial Pressure at Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inferior Vena Cava Diameter at End Expiration at Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of participants with antibody sero-conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: complete virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-hospitalization patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse maternal outcome composite
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog score during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the relapse-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Body Mass Index Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of gene expression for UCP2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected and Best corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ureteral stent symptoms questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting Post Intervention Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Length of Transition Period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PCL-M
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: task motivation to engage in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: task self-efficacy to engage in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in FEV1 AUC 0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Achievement of > 90% Donor Chimerism in T-cell Lineage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volunteer global assessment of improvement rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intrahepatic triglyceride (IHTG) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunologic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events of Grades 3 and 4 Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pure tone audiometric thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pulmonary arterial pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulmonary vascular resistance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects achieving hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-transition to overt nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anticonvulsant compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of appearances of phlebitis in the lower limbs and/or pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Actuarial Probability of Donor Hematopoietic Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Non-relapse Mortality at or Before Day 100
Endpoint domain: Mortality/survival
Primary endpoint: Change in number and type of circulating microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in blood coagulation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients attaining A1C <=7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose-area quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measurement of air Kerma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Kinematic analysis of hip movements for flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Kinematic analysis of hip movements for extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Kinematic analysis of hip movements for internal rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Kinematic analysis of hip movements for external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in quadriceps muscle layer thickness (QMLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in rectus femoris cross sectional area (RF-CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Drug-Related Select Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Surgery Delay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Investigator-Assessed Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal drainage amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPA concentration in plasma lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in peripheral blood mDC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ankle joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious, CryoBalloon Ablation System-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with baseline LGD who have complete eradication of all dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients with baseline HGD who have complete eradication of all dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of all treated patients who have complete eradication of all dysplasia (CE-D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Compliance with the WHO surgical safety checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Non-Culprit Major Adverse Cardiac Event (NC-MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lesions in foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of RV to LV Diameter Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life in patients with LBSL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ataxia in patients with LBSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Balance in patients with LBSL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Disability level
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mature follicle diameter ≥18mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Frequency of HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Biomarkers of immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Work ability score (WAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proper hand position during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants' satisfaction with the content in the mindful meditation app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants who use the mindful meditation app for the 70% of the prescribed weekly minutes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in participants' nightly sleep duration over the course of the 8-week intervention period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Total Testosterone Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Understanding of clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes towards participation in clinical research
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibodies to synapsin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Subjects With a Device and/or Procedure-related SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Subjects Free From Atrial Fibrillation (AF), Atrial Flutter (AFL) or Atrial Tachycardia (AT) Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal vessel diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants Who Achieved ACR20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients alive
Endpoint domain: Mortality/survival
Primary endpoint: Anastomotic biliary stricture resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Beat-to-beat fetal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dose of patient-controlled sedation/analgesia consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of migraine aura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in consumed BZD (diazepam equivalent) dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from 6-month participation restriction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from 6-month experience of minor stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants who complete the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of LVEF by 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease the left ventricular end-systolic dimension by 3 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grams Ethanol Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in communication during interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Shoulder internal range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycocalyx Breakdown as Assessed by Syndecan-1 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial Leakage as Assessed by Soluble Thrombomodulin (sTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation as Assessed by Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Tested Positive for EGFR Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With EGFR Mutations by Subgroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in symptom scores on Sino-nasal Outcome Test (SNOT)-22 surveys
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in symptom scores on Rhinosinusitis Disability Index (RSDI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Magnetic resonance signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Dose-Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Oxford-12 Self Assessment Form
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hearing Handicap Inventory for Adults (HHIA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hearing Aid Benefit (Abbreviated Profile of Hearing Aid Benefit, APHAB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intent to Continue Use
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change in Intrahepatic Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes